Table 1.
Summary of clinical trials of entecavir
| ALT normalization | Drop in HBV viral load (log copies/ml) | Undetectable HBV DNA by PCR | HBeAg loss | HBeAg seroconversion | HBsAg loss | HBsAg seroconversion | Histological improvement | |
|---|---|---|---|---|---|---|---|---|
| Nucleoside naïve, HBeAg positive | ||||||||
| Year 1 | ||||||||
| Chang et al12 | 68% | −6.9 | 67% | 22% | 21% | 2% | 72% | |
| Leung et al15 | 76% | 58% | 18% | 15% | Not reported | |||
| Yao et al14 | 89% | −6.0 | 74% | 18% | 15% | Not reported | ||
| Year 2 | ||||||||
| Gish et al16 | 87% | 80% | 31% | 5% | 2% | |||
| Nucleoside naïve, HBeAg negative | ||||||||
| Year 1 | ||||||||
| Lai et al13 | 78% | −5.0 | 90% | 70% | ||||
| Yao et al14 | 94% | −5.22 | 94% | Not reported | ||||
| Year 2 | ||||||||
| Shouval et al17 | 27% | 85% | 0% | |||||
| Lamivudine refractory | ||||||||
| Year 1 | ||||||||
| Chang et al10 | 68% | −5.06 | 26% | 11% | 4% | |||
| Sherman et al18 | 61% | −5.11 | 19% | 10% | 8% | 55% | ||
| Yao et al19 | 85% | −5.08 | 27% | 6% | Not reported | |||
| Suzuki et al20 | 78% | −3.75 | 33% | 15% | 60% | |||
| Year 2 | ||||||||
| Sherman et al21 | 85% | −5.9 | 30% | 16% | 1.4% | 0.7% | ||
| Yao et al22 | 80% | 47% | 13% | 11% | ||||
| Year 3 | ||||||||
| Yao et al22 | 65% | 55% | 17% | 12% | ||||
Abbreviations: ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; PCR, polymerase chain reaction.